A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Subjects with Alzheimer’s Disease.
Age: 50-90 years
No. Visits: 6
Payment: On visits 1,4,5= $75 (each visit) for Subjects & $125 (each visit) for Caregiver. Visits 2,3,6=$275 (each visit) for Subject & $325 (each visit) for Caregiver.
Type of Volunteer: Subjects with mild to moderate Insomnia
Length of Study: 6 Weeks